BridgeBio Pharma Inc. published a document on the CLARIFY disease monitoring study, which is a global, multicenter, longitudinal, non-interventional study. The study aims to understand the disease burden, management, and progression in pediatric and adult participants with Autosomal Dominant Hypocalcemia Types 1 and 2 (ADH1/2) over five years. The document includes details on the study design, methods, and baseline characteristics of pediatric participants. The full document can be accessed through the link below.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BridgeBio Pharma Inc. published the original content used to generate this news brief on July 15, 2025, and is solely responsible for the information contained therein.